House Dust Mite Allergy Market Report 2026

House Dust Mite Allergy Market Overview

• House Dust Mite Allergy market size has reached to $2.37 billion in 2025 • Expected to grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Rising Prevalence Of Asthma Diseases To Drive Market Growth • Market Trend: Innovative Sublingual Tablet Solutions For House Dust Mite Allergies • North America was the largest region in 2025 and Asia-pacific is the fastest growing region.

What Is Covered Under House Dust Mite Allergy Market?

House dust mite allergy refers to an allergic reaction to small insects that frequently reside in household dust. This includes the treatment provided for allergic reactions such as sneezing and allergy-related conditions. The main product types for house dust mite allergy are tablets, nasal drops and injectable. Tablets are a compact, solid-dose form that can include medications with or without excipients. The various treatments include medication, immunotherapy, nasal irrigation and others. The various diagnosis includes skin prick test (SPT), specific immunoglobulin E (IgE) blood test and others with various dosage forms such as solid and liquid. These are used by various end-users such as hospitals, homecare, specialty clinics and others.

What Is The House Dust Mite Allergy Market Growth Forecast?

The house dust mite allergy market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing adoption of personalized immunotherapy, rising focus on preventive allergy care, expansion of home-based allergy management, growing demand for long-term symptom control, advancements in biologic allergy treatments. Major trends in the forecast period include increasing adoption of immunotherapy-based treatments, rising use of sublingual allergy tablets, growing demand for long-term allergy management solutions, expansion of early diagnostic testing adoption, enhanced focus on personalized allergy treatment.

Global House Dust Mite Allergy Market Segmentation

1) By Product Type: Tablets, Nasal Drops, Injectable 2) By Diagnosis: Skin Prick Test (SPT), Specific Immunoglobulin E (IgE) Blood Test, Other Diagnosis 3) By Dosage Forms: Solid, Liquid 4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Tablets: Sublingual Tablets, Oral Tablets 2) By Nasal Drops: Antihistamine Nasal Drops, Corticosteroid Nasal Drops 3) By Injectable: Allergen Immunotherapy Injections, Corticosteroid Injections

What Is The Driver Of The House Dust Mite Allergy Market?

The prevalence of asthma diseases is expected to propel the growth of the house dust mite allergy market going forward. Asthma diseases refer to chronic inflammatory airway disorders characterized by recurring episodes of breathlessness, wheezing, chest tightness, and coughing. Asthma diseases are rising due to growing environmental pollution, which increases airway inflammation and heightens sensitivity to allergens. The house dust mite allergy market is witnessing increased demand as the rapid expansion of asthma diseases pushes companies to adopt solutions that reduce allergen exposure and support better respiratory health outcomes. For instance, in June 2025, according to the American Lung Association, a US-based nonprofit health organization, current asthma prevalence among adults showed substantial variation across US jurisdictions, ranging from 7.1% in Mississippi to 14.1% in Puerto Rico in 2023. Therefore, the prevalence of asthma diseases is driving the demand for the house dust mite allergy industry.

Key Players In The Global House Dust Mite Allergy Market

Major companies operating in the house dust mite allergy market are Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, GlaxoSmithKline

Global House Dust Mite Allergy Market Trends and Insights

Major companies operating in the house dust mite allergy market are focusing on developing innovative solutions, such as sublingual tablets designed to treat house dust mite allergies to address the increasing prevalence of allergies. A sublingual tablet designed to treat house dust mite allergies refers to a type of immunotherapy that involves placing a tablet under the tongue, where it dissolves and delivers small doses of the allergen responsible for triggering the allergy. For instance, in January 2023, ALK-Abelló A/S, a Denmark-based pharmaceutical company, received FDA approval for ODACTRA, a sublingual tablet designed to treat house dust mite allergies in adolescents aged 12 to 17, expanding its previous indication for adults. This approval addresses a significant need, as nearly 50% of allergy sufferers are sensitive to house dust mites. Clinical trials demonstrated that ODACTRA effectively reduced allergy symptoms, with a safety profile similar to that observed in adults. While the treatment is generally well-tolerated, patients are advised to have auto-injectable epinephrine on hand due to the potential for severe allergic reactions.

What Are Latest Mergers And Acquisitions In The House Dust Mite Allergy Market?

In September 2025, Stallergenes Greer, a France-based biopharmaceutical company specializing in allergen immunotherapy, partnered with Nuance Pharma to expand the commercialization of its house-dust-mite sublingual immunotherapy tablet, Actair, across China. Through this partnership, the companies aim to increase access to evidence-based allergy treatments and strengthen the availability of advanced immunotherapy options for patients with house dust mite–induced allergic rhinitis. Nuance Pharma is a China-based biopharmaceutical company focused on respiratory, immunology, and specialty-care therapeutics.

Regional Outlook

North America was the largest region in the house dust mite allergy market in 2025. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the House Dust Mite Allergy Market?

The house dust mite allergy market consists of sales of prescription drugs and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.